Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
| Revenue (Most Recent Fiscal Year) | $9.68M |
| Net Income (Most Recent Fiscal Year) | $-250.64M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 42.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 67.13 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -646.98% |
| Net Margin (Trailing 12 Months) | -646.99% |
| Return on Equity (Trailing 12 Months) | 717.50% |
| Return on Assets (Trailing 12 Months) | 58.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.62 |
| Inventory Turnover (Trailing 12 Months) | 0.92 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 356.51M |
| Free Float | 188.59M |
| Market Capitalization | $1.36B |
| Average Volume (Last 20 Days) | 4.45M |
| Beta (Past 60 Months) | 1.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 47.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 33.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |